TIBET PHARMA(SH:600211) Sou Hu Cai Jing·2025-10-12 17:31Core Viewpoint - Tibet Pharmaceutical (600211) reported a closing price of 48.89 yuan on October 10, 2025, with a 2.47% increase, indicating positive market sentiment and trading activity [1]. Trading Information Summary - On October 10, the net inflow of main funds was 39.73 million yuan, accounting for 7.52% of the total transaction amount [1]. - Retail investors experienced a net outflow of 41.00 million yuan, representing 7.76% of the total transaction amount [1]. Company Announcement Summary - Tibet Nodi Kang Pharmaceutical Co., Ltd. held a semi-annual performance briefing on October 10, 2025, attended by key executives to address investor inquiries [1]. - The company plans to invest several million yuan in new active substance evidence-based medical research, enhance academic promotion, and expand commercial cooperation [1]. - The existing production capacity of the new active substance is expected to meet demand, with a slight increase in annual sales compared to last year [1]. - The launch of a new production line is anticipated to improve efficiency and reduce costs [1]. - Zolizitin has initiated commercialization, with preparations for medical insurance negotiations underway, although its impact on company revenue is expected to be minimal this year [1]. - Sales of Zolizitin will adopt an agency model, with the major shareholder Kangzhe Pharmaceutical not participating in promotion [1]. - The investment in Rui Zheng Gene aligns with the company's innovative transformation strategy, aimed at enhancing R&D capabilities and expanding the product line [1]. - The overseas registration of the new active substance is under research evaluation, with international expansion to be pursued at an appropriate time [1]. - Medical insurance negotiation prices are expected to remain stable, with no significant fluctuations in sales volume [1].